This company has been marked as potentially delisted and may not be actively trading. Can B (CANB) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock CANB vs. MEDS, BIMI, SBFM, BCLI, PLRZ, APLM, KLDO, NKGN, AEZS, and HCWBShould you be buying Can B stock or one of its competitors? The main competitors of Can B include TRxADE HEALTH (MEDS), BIMI (BIMI), Sunshine Biopharma (SBFM), Brainstorm Cell Therapeutics (BCLI), Polyrizon (PLRZ), Apollomics (APLM), Kaleido Biosciences (KLDO), NKGen Biotech (NKGN), Aeterna Zentaris (AEZS), and HCW Biologics (HCWB). These companies are all part of the "medical" sector. Can B vs. Its Competitors TRxADE HEALTH BIMI Sunshine Biopharma Brainstorm Cell Therapeutics Polyrizon Apollomics Kaleido Biosciences NKGen Biotech Aeterna Zentaris HCW Biologics Can B (NASDAQ:CANB) and TRxADE HEALTH (NASDAQ:MEDS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability. Which has more volatility & risk, CANB or MEDS? Can B has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, TRxADE HEALTH has a beta of 2.32, indicating that its share price is 132% more volatile than the S&P 500. Which has stronger valuation and earnings, CANB or MEDS? Can B has higher earnings, but lower revenue than TRxADE HEALTH. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCan B$2.16M0.60-$9.74MN/AN/ATRxADE HEALTH$7.45M0.21-$17.84MN/AN/A Is CANB or MEDS more profitable? TRxADE HEALTH has a net margin of -149.81% compared to Can B's net margin of -1,238.33%. Can B's return on equity of 0.00% beat TRxADE HEALTH's return on equity.Company Net Margins Return on Equity Return on Assets Can B-1,238.33% N/A -218.65% TRxADE HEALTH -149.81%-196.79%-112.21% Does the media prefer CANB or MEDS? In the previous week, TRxADE HEALTH had 1 more articles in the media than Can B. MarketBeat recorded 1 mentions for TRxADE HEALTH and 0 mentions for Can B. TRxADE HEALTH's average media sentiment score of 0.67 beat Can B's score of -0.14 indicating that TRxADE HEALTH is being referred to more favorably in the news media. Company Overall Sentiment Can B Neutral TRxADE HEALTH Positive Do institutionals and insiders have more ownership in CANB or MEDS? 6.1% of Can B shares are owned by institutional investors. Comparatively, 5.7% of TRxADE HEALTH shares are owned by institutional investors. 11.4% of Can B shares are owned by insiders. Comparatively, 48.4% of TRxADE HEALTH shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryTRxADE HEALTH beats Can B on 7 of the 11 factors compared between the two stocks. Get Can B News Delivered to You Automatically Sign up to receive the latest news and ratings for CANB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CANB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANB vs. The Competition Export to ExcelMetricCan BDrugs, proprietaries, & sundries IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.30M$1.71M$5.82B$9.71BDividend YieldN/AN/A3.84%4.09%P/E RatioN/AN/A30.9025.97Price / Sales0.600.11469.81120.77Price / CashN/AN/A37.1558.38Price / Book-0.062.499.116.37Net Income-$9.74M-$20.12M$3.26B$265.56M Can B Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANBCan BN/A$0.02-18.0%N/A+30.5%$1.30M$2.16M0.0016Gap DownMEDSTRxADE HEALTHN/A$2.22+6.2%N/A-86.4%$3.12M$7.45M0.0050BIMIBIMIN/A$0.00-50.0%N/A-100.0%$1K$12.63M0.00520Gap DownSBFMSunshine Biopharma2.1638 of 5 stars$1.46-3.0%$15.00+930.9%-52.6%$6.63M$36.23M-0.013BCLIBrainstorm Cell Therapeutics2.3444 of 5 stars$0.60-8.5%N/A-88.4%$6.62MN/A-0.1840Short Interest ↓PLRZPolyrizonN/A$1.10+8.4%N/AN/A$6.56MN/A0.00N/AAPLMApollomics0.0601 of 5 stars$5.85+0.8%N/A-53.8%$6.43M$1.49M0.0045Positive NewsGap UpKLDOKaleido BiosciencesN/AN/AN/AN/A$6.39M$1.10M0.0080NKGNNKGen BiotechN/A$0.14-17.6%N/A-83.7%$6.29MN/A-0.03N/AGap DownAEZSAeterna ZentarisN/A$3.50-1.7%N/A-52.6%$6.28M$2.37M-0.2420HCWBHCW Biologics2.148 of 5 stars$4.35-3.2%$35.00+705.5%-80.7%$6.26M$1.45M-0.1940Earnings ReportShort Interest ↑Gap Down Related Companies and Tools Related Companies MEDS Competitors BIMI Competitors SBFM Competitors BCLI Competitors PLRZ Competitors APLM Competitors KLDO Competitors NKGN Competitors AEZS Competitors HCWB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CANB) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can B Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can B With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access